Edition:
United States

EnteroMedics Inc (ETRM.OQ)

ETRM.OQ on NASDAQ Stock Exchange Capital Market

5.08USD
23 May 2017
Change (% chg)

-- (--)
Prev Close
$5.08
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
329,495
52-wk High
$56.00
52-wk Low
$1.76

Latest Key Developments (Source: Significant Developments)

Enteromedics announces the acquisition of the Gastric Vest System
Tuesday, 23 May 2017 07:00am EDT 

May 23 (Reuters) - Enteromedics Inc : :Enteromedics announces the acquisition of the Gastric Vest System.Enteromedics - shares of common stock issued in acquisition represent 19.99pct of Enteromedics' outstanding common stock immediately prior to acquisition.Enteromedics Inc - it has acquired Gastric Vest System through its acquisition of Bariosurg Inc.Enteromedics - consideration paid for Bariosurg consists of 1.38 million unregistered shares of co's common stock, 1.0 million unregistered shares convertible preferred stock & $2.0 million in cash.  Full Article

EnteroMedics Q1 loss per share $1.27
Tuesday, 16 May 2017 07:00am EDT 

May 16 (Reuters) - EnteroMedics Inc :Q1 loss per share $1.27.Enteromedics inc - for three months ended march 31, 2017, company reported sales of $40,000 with gross profits totaling $11,000.Enteromedics inc - on march 31, 2017, company's cash, cash equivalents and short-term investments totaled $18.7 million.  Full Article

Enteromedics Inc files for a mixed shelf of upto $75 mln - SEC filing
Friday, 10 Mar 2017 03:40pm EST 

Enteromedics Inc :Files for a mixed shelf of upto $75 million - SEC filing.  Full Article

Enteromedics Q4 sales $141,900
Tuesday, 7 Mar 2017 07:00am EST 

Enteromedics Inc : Enteromedics reports fourth quarter 2016 financial results . Q4 loss per share $2.65 including items . Q4 sales $141,900 .Enteromedics Inc says on December 31, 2016, company's cash, cash equivalents and short-term investments totaled $3.3 million.  Full Article

EnteroMedics announces 1-for-70 reverse stock split
Friday, 23 Dec 2016 07:00am EST 

EnteroMedics Inc - : Declared a 1-for-70 reverse stock split of co's common stock, will be effective for trading purposes upon commencement of trading on Dec 28 . Used net proceeds from the offering to continue its commercialization efforts for vbloc neurometabolic therapy . Announced that all $18.75 million of its senior amortizing convertible notes will be converted as of tuesday, December 27, 2016 . Under terms of securities purchase deal, co issued $1.5 million of notes at initial closing, balance issued in 2 tranches of $11.0 million, $6.25 million .Enteromedics announces 1-for-70 reverse stock split.  Full Article

EnteroMedics says Commercial Patient Data confirms success of co's vBloc therapy in combination with vBloc achieve program
Thursday, 15 Dec 2016 07:00am EST 

EnteroMedics Inc :Commercial Patient Data confirms success of EnteroMedics' vBloc therapy in combination with vBloc achieve program in patients struggling to lose weight.  Full Article

CVI Investments Inc reports 9.9 pct passive stake in Enteromedics Inc
Friday, 26 Aug 2016 09:44am EDT 

: CVI Investments Inc reports 9.9 pct passive stake in enteromedics inc, as of August 18, 2016 - Sec Filing Source - http://bit.ly/2cetnP4 Further company coverage: [ETRM.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Enteromedics Q2 loss per share $0.49
Thursday, 4 Aug 2016 07:00am EDT 

Enteromedics Inc : Enteromedics reports second quarter 2016 financial results . Q2 loss per share $0.49 .Q2 sales $276,000.  Full Article

EnteroMedics says CFP Greg Lea to retire effective as of October 1, 2016
Wednesday, 6 Jul 2016 05:11pm EDT 

Enteromedics Inc :On june 30, greg lea, co's cfo said intends to retire and leave his position with company effective as of october 1, 2016 - sec filing.  Full Article

EnteroMedics Inc reports $25 mln notes offering
Thursday, 5 Nov 2015 09:05am EST 

EnteroMedics Inc:Announces $25.0 million registered direct offering of convertible notes.Says intends to hold a special shareholder meeting to authorize the company to carry out a reverse stock split.To use net proceeds to continue commercialization efforts for maestro rechargeable system,for clinical product development activities.  Full Article

More From Around the Web